Response of osteogenic sarcoma to neoadjuvant therapy: evaluated by 18F-FDG-PET
- 139 Downloads
The aim of this study was to evaluate the potential role of F-18-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) in assessing the chemotherapy response of osteosarcoma when compared with histologically assessed tumor necrosis.
Fifteen patients were examined with whole-body FDG-PET prior to and following neoadjuvant therapy. The maximum standard uptake value (SUVmax) of tumor and tumor to background ratio (TBR) prior to and following chemotherapy was used for semiquantitative PET imaging analysis. The SUVmax of prechemotherapy and post-chemotherapy was recorded as SUV1 and SUV2. TBR1 and TBR2 represented prechemotherapy and post-chemotherapy TBR. TBR was calculated by drawing an identical region of interest over the tumor and the contralateral normal limb or pelvis. Tumor necrosis was classified according to Salzer-Kuntschik’s criteria.
Eight patients with more than 90% tumor necrosis were classified as showing good responses and seven patients with less than 90% tumor necrosis as showing poor responses. SUV2/SUV1, TBR2/TBR1, and TBR2 were significantly correlated with the tumor necrosis degree (P < 0.01, P < 0.001, P < 0.001). TBR2/TBR1 were below 0.46 in all the patients with favorable responses, and higher than 0.49 in all the patients with unfavorable responses. However, it was difficult to distinguish good responses from poor responses by SUV2/SUV1.
FDG-PET is a promising tool to assess the chemotherapy response of osteosarcoma noninvasively. The TBR was better than SUVmax in evaluating the chemotherapy response in this study.
KeywordsChemotherapy Osteosarcoma Necrosis FDG-PET
Unable to display preview. Download preview PDF.
- 2.Bielack S, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002;20:776–790.PubMedCrossRefGoogle Scholar
- 5.Schwarz JD, Bader M, Jenicke L, Hemminger G, Janicke F, Avril N. Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG-PET. J Nucl Med 2005;46:1144–1150.Google Scholar
- 8.Levine EA, Farmer MR, Clark P, Mishra G, Ho C, Geisinger KR. Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer. Ann Surg 2006;243:472–478.PubMedCrossRefGoogle Scholar
- 12.Tateishi U, Yamaguchi U, Seki U, Terauchi T, Arai Y, Hasegawa T. Glut-1 expression and enhanced glucose metabolism are associated with tumour grade in bone and soft tissue [18F]fluorodeoxyglucose sarcomas: a prospective evaluation by positron emission tomography. Eur J Nucl Med Mol Imaging 2006;33:683–691.PubMedCrossRefGoogle Scholar
- 21.Abella E, Dicarli M, Ravindranath Y, Kottamasu S, Muzik O, Decamilo D, et al. Positron emission tomography [PET] scanning with 18-fluorodeoxyglcose[FDG] correlates with histological response in children with osteosarcoma [OS] and Ewing’s sarcoma [ES]. Proc Annu Meet Am Soc Clin Oncol 1996;15:1457.Google Scholar